Acadia to Move Experimental Pediatric Rett Syndrome Drug to Phase 3

Acadia to Move Experimental Pediatric Rett Syndrome Drug to Phase 3

Play Episode Pause Episode

Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds

00:00 /

RSS Feed

Share

Link

Embed

Acadia Pharmaceuticals said it plans to advance a drug it licensed last year from Australia?s Neuren Pharmaceuticals into a late-stage trial following promising Phase 2 results of the potential Rett syndrome treatment. San Diego-based Acadia (NASDAQ: ACAD) announced in August that it had licensed the drug, trofinetide, for development and commercialization in North America as [?]